Drugs / MEDI4276
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02576548 | Sep 2015 → May 2018 | carcinoma | MedImmune LLC | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2016-04-14 | AstraZeneca | Results AstraZeneca showcases breadth of Oncology portfolio at AACR 2016 Annual Meeting astrazeneca.com ↗
MEDI4276, a HER2-targeting antibody tubulysin conjugate, displays potent in vitro and in vivo activity in preclinical studies |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2016-04-14 | AstraZeneca | AstraZeneca showcases breadth of Oncology portfolio at AACR 2016 Annual Meeting astrazeneca.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MEDI4276 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02576548 ↗ |
| Route | Intravenous | “Participants received IV dose of 0.05 mg/kg MEDI4276 every three weeks (Q3W) for 2 years.” NCT02576548 ↗ |
| Target | ERBB2 | “MEDI4276, an Antibody-Drug Conjugate of Tubulysin Analogue Attached via Cleavable Linker to a Biparatopic Humanized Antibody against HER-2.” PMID 31544817 ↗ Jan 2019 |